Mirum Pharmaceuticals (MIRM) Projected to Post Quarterly Earnings on Wednesday

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) is projected to announce its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $96.64 million for the quarter. Investors that are interested in participating in the company's conference call can do so using this link.

Mirum Pharmaceuticals Stock Down 1.2 %

Shares of NASDAQ:MIRM traded down $0.66 during trading on Friday, reaching $52.50. 940,110 shares of the company traded hands, compared to its average volume of 524,750. The firm has a fifty day simple moving average of $46.01 and a 200 day simple moving average of $42.97. The firm has a market cap of $2.52 billion, a P/E ratio of -25.99 and a beta of 0.96. Mirum Pharmaceuticals has a 1-year low of $23.14 and a 1-year high of $54.23. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33.

Insider Buying and Selling

In other news, CEO Christopher Peetz sold 7,489 shares of the business's stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total transaction of $320,678.98. Following the transaction, the chief executive officer now owns 119,359 shares in the company, valued at approximately $5,110,952.38. The trade was a 5.90 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Jolanda Howe sold 750 shares of the business's stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $32,115.00. Following the transaction, the senior vice president now owns 2,926 shares in the company, valued at approximately $125,291.32. The trade was a 20.40 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 40,915 shares of company stock worth $1,897,920 in the last quarter. 22.87% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms recently issued reports on MIRM. Citigroup lifted their price objective on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a "buy" rating in a research note on Wednesday, November 13th. HC Wainwright reaffirmed a "buy" rating and issued a $66.00 price objective on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Finally, Robert W. Baird lifted their price objective on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an "outperform" rating in a research note on Wednesday, November 13th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $57.10.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.